{"id":75201,"date":"2026-08-18T12:08:56","date_gmt":"2026-08-18T04:08:56","guid":{"rendered":"https:\/\/flcube.com\/?p=75201"},"modified":"2026-08-18T12:08:57","modified_gmt":"2026-08-18T04:08:57","slug":"ledeinno-medical-valley-closes-over-200-million-rmb-in-series-b-and-b-rounds-shining-capital-leads-backing-for-wireless-scs-neuromodulation-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75201","title":{"rendered":"Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds \u2013 Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform"},"content":{"rendered":"\n

Ledeinno Medical Valley<\/strong> announced the completion of its Series B+ and Series B++ funding rounds totaling over 200 million RMB<\/strong>. The Series B+ round<\/strong> was funded by Shining Capital<\/strong>, while the Series B++ round<\/strong> was jointly invested by Chuangjing Capital<\/strong> and funds managed by CICC Capital<\/strong>. Genesis Partners<\/strong> served as the exclusive financial advisor. Proceeds will be deployed across registration, commercialization and next\u2011generation R&D of the company’s wireless implantable neurostimulation portfolio.<\/p>\n\n\n\n

Funding Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Rounds<\/strong><\/td>Series B+ and Series B++<\/td><\/tr>
Total Size<\/strong><\/td>Over 200 million RMB<\/td><\/tr>
Series B+ Investor<\/strong><\/td>Shining Capital<\/td><\/tr>
Series B++ Investors<\/strong><\/td>Chuangjing Capital; funds managed by CICC Capital<\/td><\/tr>
Financial Advisor<\/strong><\/td>Genesis Partners (exclusive)<\/td><\/tr>
Announcement Date<\/strong><\/td>17 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Use of Proceeds<\/h2>\n\n\n\n
    \n
  1. SCS Commercialization:<\/strong> Accelerate the registration filing and commercialization of the implantable wireless spinal cord stimulation (SCS) system<\/strong>.<\/li>\n\n\n\n
  2. PNS Development:<\/strong> Conduct clinical research and registration translation for the implantable wireless peripheral nerve stimulation (PNS) system<\/strong>.<\/li>\n\n\n\n
  3. Frontier R&D:<\/strong> Increase R&D and clinical translation investments in cutting\u2011edge products, including closed\u2011loop neuromodulation<\/strong>, brain\u2011computer interfaces (BCIs)<\/strong> and brain\u2011spine interfaces<\/strong>.<\/li>\n<\/ol>\n\n\n\n

    Company & Technology Profile<\/h2>\n\n\n\n